JPWO2021050649A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021050649A5
JPWO2021050649A5 JP2022515692A JP2022515692A JPWO2021050649A5 JP WO2021050649 A5 JPWO2021050649 A5 JP WO2021050649A5 JP 2022515692 A JP2022515692 A JP 2022515692A JP 2022515692 A JP2022515692 A JP 2022515692A JP WO2021050649 A5 JPWO2021050649 A5 JP WO2021050649A5
Authority
JP
Japan
Prior art keywords
eye
raav particles
sequence
unit dose
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022515692A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022547541A (ja
JP2022547541A5 (https=
Publication date
Priority claimed from PCT/US2019/062066 external-priority patent/WO2021050094A1/en
Application filed filed Critical
Priority claimed from PCT/US2020/050079 external-priority patent/WO2021050649A1/en
Publication of JP2022547541A publication Critical patent/JP2022547541A/ja
Publication of JP2022547541A5 publication Critical patent/JP2022547541A5/ja
Publication of JPWO2021050649A5 publication Critical patent/JPWO2021050649A5/ja
Priority to JP2025077233A priority Critical patent/JP2025118798A/ja
Withdrawn legal-status Critical Current

Links

JP2022515692A 2019-09-11 2020-09-10 アフリベルセプトをコードするaav2バリアントを使用して眼内血管新生疾患を処置する方法 Withdrawn JP2022547541A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025077233A JP2025118798A (ja) 2019-09-11 2025-05-07 アフリベルセプトをコードするaav2バリアントを使用して眼内血管新生疾患を処置する方法

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US201962899070P 2019-09-11 2019-09-11
US62/899,070 2019-09-11
US201962913648P 2019-10-10 2019-10-10
US62/913,648 2019-10-10
USPCT/US2019/062066 2019-11-18
PCT/US2019/062066 WO2021050094A1 (en) 2019-09-11 2019-11-18 Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept
US202062959784P 2020-01-10 2020-01-10
US62/959,784 2020-01-10
US202062971835P 2020-02-07 2020-02-07
US62/971,835 2020-02-07
US202063019190P 2020-05-01 2020-05-01
US63/019,190 2020-05-01
US202063030819P 2020-05-27 2020-05-27
US63/030,819 2020-05-27
US202063063203P 2020-08-07 2020-08-07
US63/063,203 2020-08-07
PCT/US2020/050079 WO2021050649A1 (en) 2019-09-11 2020-09-10 Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025077233A Division JP2025118798A (ja) 2019-09-11 2025-05-07 アフリベルセプトをコードするaav2バリアントを使用して眼内血管新生疾患を処置する方法

Publications (3)

Publication Number Publication Date
JP2022547541A JP2022547541A (ja) 2022-11-14
JP2022547541A5 JP2022547541A5 (https=) 2023-08-24
JPWO2021050649A5 true JPWO2021050649A5 (https=) 2023-08-24

Family

ID=72644941

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022515692A Withdrawn JP2022547541A (ja) 2019-09-11 2020-09-10 アフリベルセプトをコードするaav2バリアントを使用して眼内血管新生疾患を処置する方法
JP2025077233A Pending JP2025118798A (ja) 2019-09-11 2025-05-07 アフリベルセプトをコードするaav2バリアントを使用して眼内血管新生疾患を処置する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025077233A Pending JP2025118798A (ja) 2019-09-11 2025-05-07 アフリベルセプトをコードするaav2バリアントを使用して眼内血管新生疾患を処置する方法

Country Status (18)

Country Link
EP (2) EP4027983B1 (https=)
JP (2) JP2022547541A (https=)
KR (1) KR20220062353A (https=)
CN (1) CN114375195A (https=)
AU (1) AU2020345915A1 (https=)
BR (1) BR112022004027A2 (https=)
CA (1) CA3148376A1 (https=)
DK (1) DK4027983T3 (https=)
ES (1) ES3063491T3 (https=)
FI (1) FI4027983T3 (https=)
HR (1) HRP20260137T1 (https=)
IL (1) IL291182A (https=)
LT (1) LT4027983T (https=)
MX (1) MX2022002961A (https=)
PT (1) PT4027983T (https=)
RS (1) RS67774B1 (https=)
SM (1) SMT202600070T1 (https=)
WO (1) WO2021050649A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118718181A (zh) 2019-06-05 2024-10-01 里珍纳龙药品有限公司 用于精确剂量递送的装置及方法
JP7842082B2 (ja) * 2020-07-21 2026-04-07 エフティージェン コーポレーション 眼疾患を処置するための組成物および方法
JP2024515459A (ja) 2021-04-27 2024-04-10 アドヴェラム バイオテクノロジーズ, インコーポレイテッド アフリベルセプトをコードするaav2バリアントを使用する眼疾患の治療方法
MX2023014041A (es) * 2021-05-28 2023-12-15 Shanghai Regenelead Therapies Co Ltd Virus adenoasociado recombinante que tiene una capsida variante y su aplicacion.
WO2023028457A1 (en) * 2021-08-23 2023-03-02 Duke University Compositions for and methods of long-term integration of circuits using connexins
EP4479098A1 (en) * 2022-02-16 2024-12-25 Adverum Biotechnologies, Inc. Method of reducing cst fluctuation in neovascular amd by a recombinant adeno-associated virus
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
WO2025026182A1 (zh) 2023-08-01 2025-02-06 北京因诺惟康医药科技有限公司 融合多肽、包含其编码基因的表达盒、基因递送载体、药物组合物及用途
KR20260004635A (ko) * 2024-07-01 2026-01-09 삼성바이오에피스 주식회사 애플리버셉트를 암호화하는 코돈-최적화된 폴리뉴클레오티드를 포함하는 발현 카세트 및 이를 포함하는 rAAV 생산용 플라스미드

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2544136B2 (ja) * 1986-05-23 1996-10-16 第一製薬株式会社 硫酸化多糖体ds4152を含有する血管新生抑制剤及び抗腫瘍剤
TW201105363A (en) * 2009-07-14 2011-02-16 Univ Yamagata Eye drop for macular edema treatment
HRP20171334T1 (hr) 2011-04-22 2017-11-17 The Regents Of The University Of California Virioni adeno-povezanog virusa s kapsid varijantom i postupci njihove upotrebe
AU2014252808A1 (en) * 2013-04-09 2015-11-12 Cresset Biomolecular Discovery Ltd The treatment of inflammatory disorders
DK3471780T3 (da) * 2016-06-16 2020-11-23 Adverum Biotechnologies Inc Behandling af amd med aav2-variant med aflibercept
CN110546257B (zh) 2017-03-17 2024-03-01 阿德夫拉姆生物技术股份有限公司 用于增强基因表达的组合物和方法

Similar Documents

Publication Publication Date Title
JP7492556B2 (ja) 滲出型加齢性黄斑変性の治療のための組成物
FI4027983T3 (fi) Silmän neovaskulaaristen sairauksien hoito afliberseptiä koodaavilla aav2-varianteilla
JP2021503914A5 (https=)
US20240108669A1 (en) Adeno-associated virus vector pharmaceutical composition and methods
RU2018142768A (ru) Варианты капсидов аденоассоциированного вируса и способы их применения
FI3717636T3 (fi) Adenoassosioidun viruksen kapsidivariantteja ja käyttö angiogeneesin estämisessä
US20110117189A1 (en) Ophthalmic compositions for treating pathologies of the posterior segment of the eye
CA3091250A1 (en) Non-viral dna vectors and uses thereof for antibody and fusion protein production
JP2021511030A5 (https=)
JPWO2021050649A5 (https=)
US20200297869A1 (en) Sequential intravitreal administration of aav gene therapy to contralateral eyes
US20220323587A1 (en) Dissolvable films and methods of their use
KR20230131246A (ko) 파브리병을 치료하기 위한 조성물 및 방법
US20160324986A1 (en) Compositions and methods for providing active telomerase to cells in vivo
JPWO2022232790A5 (https=)
JPWO2023150566A5 (https=)
JPWO2023158990A5 (https=)
JP7766054B2 (ja) 眼病態の処置のためのdna構造
JPWO2021041373A5 (https=)
Kirkner Pipeline report: new entries continue to exceed exits
Chan Association for Research in Vision and Ophthalmology (ARVO) 2017 Annual Meeting. Baltimore, Maryland, USA-May 7-11, 2017
JPWO2020236352A5 (https=)
Toprak ANTI-VEGF AND STEROID THERAPY IN DIABETIC RETINOPATHY
JPWO2021069523A5 (https=)
RU2025139063A (ru) Препараты аденоассоциированных вирусов